Agios Pharmaceuticals Inc

AGIONASDAQ · USD
29.68USD0.00 (-0.71%)
235

Agios Pharmaceuticals Inc (AGIO) Covered Calls

Agios Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 98.81%, high versus the past year. AGIO's highest covered call setup is the $45.00 strike expiring Feb 19, 2027, sorted by theoretical annualized return. It's 50.55% out of the money with 94 days to expiration, a 55.24% return until expiration, and a 214.48% theoretical annualized return. Across the setups shown, annualized returns run from 59.95% to 214.48% at strikes between $30.00 and $55.00, with 3 to 430 days to expiration, as of Nov 17, 2026.

Read more

Running AGIO covered calls helps you generate income from Agios Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AGIO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AGIO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AGIO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AGIO covered call is worth writing.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

2027-02-199445.0050.551.402.251651.0055.24214.48-4.68+0.272,8080.85
2026-12-183135.0017.100.250.60536.0017.93211.14-0.84+0.184850.35
2026-11-20330.000.370.350.7546.001.54187.24-1.17+0.484560.40
2027-02-199440.0033.820.903.901101.0036.84143.03-3.01+0.342253.00
2027-05-2118550.0067.280.105.002021.0067.61133.40-0.33+0.3054.90
2027-02-199435.0017.103.805.30891.0029.81115.75-12.71+0.491051.50
2027-05-2118545.0050.550.504.901561.0052.22103.04-1.67+0.3304.40
2027-05-2118540.0033.821.356.001146.0038.3475.64-4.52+0.41114.65
2028-01-2143055.0084.010.505.502561.0085.6872.73-1.67+0.3115.00
2028-01-2143050.0067.281.006.002111.0070.6359.95-3.35+0.36175.00

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank98.81% High
  • Market cap (M$)1,775
  • 52 weeks high-32.68%
  • 52 weeks low33.45%
  • Analyst recommendationStrong Buy
    1.44
  • Target price$47.00
    58.36% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2027-02-11
  • P/E—
  • Future P/E—
  • EPS (ttm)-6.32
  • EPS growth next 5 years41.61%

As of Nov 17, 2026